EcoDrugPlus

Peptidyl-Prolyl Cis-Trans Isomerase A-Like

Ensembl ID : ENSMAUG00000020230
Gene Symbol: LOC106022166
2 Cross references
289 Possible Orthologues:

Peptidylprolyl Isomerase A

Ensembl ID : ENSMAUG00000019015
Gene Symbol: PPIA
2 Cross references
300 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSMAUG00000005745
Gene Symbol: PPARA
3 Cross references
453 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSMAUG00000004049
Gene Symbol: PPARD
4 Cross references
418 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSMAUG00000012323
Gene Symbol: PPARG
2 Cross references
405 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSMAUG00000019874
Gene Symbol: PIK3CA
4 Cross references
275 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSMAUG00000006981
Gene Symbol: PIK3CB
4 Cross references
215 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSMAUG00000001319
Gene Symbol: PIK3CD
4 Cross references
213 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSMAUG00000000671
Gene Symbol: PIK3CG
4 Cross references
213 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSMAUG00000000760
Gene Symbol: PDE10A
4 Cross references
205 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSMAUG00000022096
Gene Symbol: PDE3A
4 Cross references
272 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSMAUG00000013828
Gene Symbol: PDE4A
4 Cross references
275 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).